Testosterone therapy reduces insulin resistance in men with adult-onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open-label phase

Testosterone therapy was found to significantly reduce insulin resistance in men with metabolic syndrome (MetS) and hypogonadism, particularly in those not receiving antiglycaemic therapy. The study, a randomized controlled trial, included 184 men, with 113 receiving testosterone undecanoate (TU) and 71 receiving placebo. Results showed a significant reduction in HOMA-IR,